DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

8 Drugs in Development

8 Drugs in Development

DIGITAL CONTENT

12 NEWS #PharmaBuzz

media
12 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

8DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Cyc065, 1070790-89-4, Cyc-065, Fadraciclib , cyc065, Yet2xnu791

Molecular Formula

C₂₁H₃₁N₇O

Molecular Weight

397.5 g/mol

InChI Key

DLPIYBKBHMZCJI-WBVHZDCISA-N

FDA UNII

YET2XNU791

Fadraciclib is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities. Upon oral administration, fadraciclib selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types; they play key roles in tumor cell proliferation, the regulation of transcription, and DNA damage repair.

1 2D Structure

Fadraciclib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2R,3S)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol

2.1.2 InChI

InChI=1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)/t15-,17+/m1/s1

2.1.3 InChI Key

DLPIYBKBHMZCJI-WBVHZDCISA-N

2.1.4 Canonical SMILES

CCC(C(C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=C(C=C3C)C

2.1.5 Isomeric SMILES

CC[C@@H]([C@@H](C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=C(C=C3C)C

2.2 Other Identifiers

2.2.1 UNII

YET2XNU791

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Cyc065

2.3.2 Depositor-Supplied Synonyms

1. Cyc065

2. 1070790-89-4

3. Cyc-065

4. Fadraciclib

5. Cyc065

6. Yet2xnu791

7. (2r,3s)-3-((6-(((4,6-dimethylpyridin-3-yl)methyl)amino)-9-isopropyl-9h-purin-2-yl)amino)pentan-2-ol

8. 1070790-89-4 (free Base)

9. (2r,3s)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol

10. 2-pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9h-purin-2-yl)amino)-, (2r,3s)-

11. Cyc065 Free Base

12. Cyc-065 Free Base

13. Fadraciclib [inn]

14. Unii-yet2xnu791

15. Fadraciclib [who-dd]

16. Chembl3655762

17. Schembl13300946

18. Gtpl10461

19. Bdbm106950

20. Bcp19571

21. Ex-a2830

22. Nsc806387

23. Cs-7615

24. Db15425

25. Nsc-806387

26. Ac-31595

27. Bc175840

28. Hy-101212

29. Us8592581, 1

30. A903453

2.4 Create Date

2008-10-27

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₃₁N₇O
Molecular Weight	397.5 g/mol
XLogP3	3.3
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	8
Exact Mass	397.25900864 g/mol
Monoisotopic Mass	397.25900864 g/mol
Topological Polar Surface Area	101 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	507
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1